Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Children's Hospital of Fudan University | Tongji Hospital | Children's Hospital of Nanjing Medical University | Jiangxi Province Children's Hospital | Chengdu Women's and Children's Central Hospital | Shandong Provincial Hospital | Shengjing Hospital | Sh
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
April 29, 2022
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Children's Hospital of Fudan University | Tongji Hospital | Children's Hospital of Nanjing Medical University | Jiangxi Province Children's Hospital | Chengdu Women's and Children's Central Hospital | Shandong Provincial Hospital | Shengjing Hospital | Sh
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Children's Hospital of Fudan University | Tongji Medical College, Huazhong University of Science and Technology | Beijing Children's Hospital | Peking University First Hospital | Peking Union Medical College Hospital | The Children's Hospital of Zhejiang
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
June 12, 2018
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Children's Hospital of Fudan University | Tongji Medical College, Huazhong University of Science and Technology | Beijing Children's Hospital | Peking University First Hospital | Peking Union Medical College Hospital | The Children's Hospital of Zhejiang
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Children's Hospital of Fudan University | Beijing Children's Hospital | Shanghai Children's Hospital | Xin Hua Hospital, Shanghai Jiaotong University School of Medicine | The Children's Hospital of Zhejiang University School of Medicine | Children's Hospi
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
May 24, 2018
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Children's Hospital of Fudan University | Beijing Children's Hospital | Shanghai Children's Hospital | Xin Hua Hospital, Shanghai Jiaotong University School of Medicine | The Children's Hospital of Zhejiang University School of Medicine | Children's Hospi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Tongji Hospital | Beijing Children's Hospital | The First Affiliated Hospital with Nanjing Medical University | Shanghai Children's Hospital | The Children's Hospital of Zhejiang University School of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
August 10, 2017
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Tongji Hospital | Beijing Children's Hospital | The First Affiliated Hospital with Nanjing Medical University | Shanghai Children's Hospital | The Children's Hospital of Zhejiang University School of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : EMD Serono
Deal Size : Inapplicable
Deal Type : Inapplicable
Impact of Recombinant Human Growth Hormone on HIV Persistence
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
March 27, 2017
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : EMD Serono
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Undisclosed
Sponsor : Peking University Third Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
June 16, 2016
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Sponsor : Peking University Third Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Long Term Study of Genotropin (Somatropin) for Short Children Born Small for Gestational Age (SGA)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 22, 2013
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
May 24, 2012
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Growth Hormone on Early Brain Development in Girls With Turner Syndrome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
June 07, 2011
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : EMD Serono
Deal Size : Inapplicable
Deal Type : Inapplicable
Growth Hormone for Poor Responders in in Vitro Fertilization (IVF)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
September 17, 2010
Lead Product(s) : Recombinant Human Growth Hormone
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : EMD Serono
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
